These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21751748)

  • 1. Cladribine: limited evaluation in multiple sclerosis.
    Prescrire Int; 2011; 20(118):175. PubMed ID: 21751748
    [No Abstract]   [Full Text] [Related]  

  • 2. Cladribine for multiple sclerosis: review and current status.
    Sipe JC
    Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
    Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617
    [No Abstract]   [Full Text] [Related]  

  • 4. Cladribine as a therapeutic option in multiple sclerosis.
    Warnke C; Leussink VI; Goebels N; Aktas O; Boyko A; Kieseier BC; Hartung HP
    Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B
    Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of cladribine treatment in multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP; Weissert R
    Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cladribine. Ortho Biotech Inc.
    Tortorella C; Rovaris M; Filippi M
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1751-6. PubMed ID: 11892941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Emerging treatments for multiple sclerosis].
    Nau JY
    Rev Med Suisse; 2010 Jun; 6(251):1162-3. PubMed ID: 20572362
    [No Abstract]   [Full Text] [Related]  

  • 11. [A plan for risk management in the treatment of multiple sclerosis with movectro (cladribine tablets)].
    Khachanova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):99-104. PubMed ID: 21916164
    [No Abstract]   [Full Text] [Related]  

  • 12. Histological examination of the retinal ganglion layer in rabbits after experimental administration of the new immunosuppressive medicine--Cladribine.
    Kwietniewska M; Cybulska R; Kwietniewski P; Sekita-Krzak J; Czerny K
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):376-80. PubMed ID: 12898865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].
    Grieb P; Stelmasiak Z
    Neurol Neurochir Pol; 1995; 29(1):69-76. PubMed ID: 7596480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunosuppressants and multiple sclerosis].
    Ruiz-Peña JL; Izquierdo-Ayuso G
    Rev Neurol; 2002 Aug 16-31; 35(4):373-80. PubMed ID: 12235571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunosuppressive medication in multiple sclerosis].
    García Merino JA
    Rev Neurol; 2002 Dec 16-31; 35(12):1154-8. PubMed ID: 12497298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of oral cladribine for the treatment of multiple sclerosis.
    Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC
    J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of chronic progressive multiple sclerosis with cladribine.
    Beutler E; Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1716-20. PubMed ID: 8643695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.